HUP0600120A2 - New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it - Google Patents

New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it

Info

Publication number
HUP0600120A2
HUP0600120A2 HU0600120A HUP0600120A HUP0600120A2 HU P0600120 A2 HUP0600120 A2 HU P0600120A2 HU 0600120 A HU0600120 A HU 0600120A HU P0600120 A HUP0600120 A HU P0600120A HU P0600120 A2 HUP0600120 A2 HU P0600120A2
Authority
HU
Hungary
Prior art keywords
producing
pharmaceutical composition
composition containing
new crystalline
atorvastatin hemicalcium
Prior art date
Application number
HU0600120A
Other languages
Hungarian (hu)
Inventor
Jozsef Dr Barkoczy
Nagy Peter Dr Kotay
Simig Gyula Dr
Judit Cselenyak
Zsuzsanna Szent-Kirallyi
Ferenc Bartha
Zoltan Katona
Dr Donath Gyoergyi Vereczkeyne
Kalman Dr Nagy
Norbert Nemeth
Gyoergy Ruzsics
Original Assignee
Egyt Gyogyszervegyeszeti Gyar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar
Priority to HU0600120A priority Critical patent/HUP0600120A3/en
Priority to US11/887,890 priority patent/US20090215855A1/en
Priority to RU2007140797/04A priority patent/RU2409563C2/en
Priority to CZ20070772A priority patent/CZ2007772A3/en
Priority to ROA200700700A priority patent/RO123642B1/en
Priority to JP2008504860A priority patent/JP5523699B2/en
Priority to EA200702191A priority patent/EA014079B1/en
Priority to EP06727218.7A priority patent/EP1868993B1/en
Priority to PCT/HU2006/000026 priority patent/WO2006106372A1/en
Priority to SK5125-2007A priority patent/SK288276B6/en
Publication of HU0600120D0 publication Critical patent/HU0600120D0/en
Publication of HUP0600120A2 publication Critical patent/HUP0600120A2/en
Priority to IL186499A priority patent/IL186499A/en
Priority to NO20075721A priority patent/NO20075721L/en
Priority to BG10109992A priority patent/BG66035B1/en
Priority to HK08105767.2A priority patent/HK1117141A1/en
Publication of HUP0600120A3 publication Critical patent/HUP0600120A3/en

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Crystalline polymorph B-52 form of atorvastatin hemicalcium salt [(beta R, delta R)-2-(4-fluorophenyl)-beta ,delta -dihydroxy-5-(1-methylethyl)-3-phenyl-4-{(phenylamino)-carbonyl}-1H-pyrrole-1-heptanoic acid hemicalcium salt] (I) and its solvates having an X-ray diffraction pattern is new. Independent claims are also included for the following: (1) preparation of (I); and (2) medicinal preparations (M1) comprising (I) and vehicles or auxiliary agents. ACTIVITY : Antilipemic. MECHANISM OF ACTION : 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitor.
HU0600120A 2005-04-08 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it HUP0600120A3 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
HU0600120A HUP0600120A3 (en) 2006-02-14 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
EP06727218.7A EP1868993B1 (en) 2005-04-08 2006-04-07 Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form
PCT/HU2006/000026 WO2006106372A1 (en) 2005-04-08 2006-04-07 New crystalline atorvastatin hemicalcium salt polymorph form
CZ20070772A CZ2007772A3 (en) 2005-04-08 2006-04-07 Novel crystalline polymorphous form of atorvastatin hemicalcium salt
ROA200700700A RO123642B1 (en) 2005-04-08 2006-04-07 Process for preparing a new crystalline atorvastatin hemicalcium salt polymorph form
JP2008504860A JP5523699B2 (en) 2005-04-08 2006-04-07 A new crystalline polymorph of atorvastatin hemi-calcium salt
EA200702191A EA014079B1 (en) 2005-04-08 2006-04-07 New crystalline atorvastatin hemicalcium salt polymorph form
US11/887,890 US20090215855A1 (en) 2005-04-08 2006-04-07 New Crystalline Atorvastatin Hemicalcium Salt Polymorph Form
RU2007140797/04A RU2409563C2 (en) 2005-04-08 2006-04-07 Novel polymorphous form of crystalline hemicalcium salt of atorvastatin
SK5125-2007A SK288276B6 (en) 2005-04-08 2006-04-07 Process for preparation of crystalline atorvastatin hemicalcium salt polymorph form
IL186499A IL186499A (en) 2005-04-08 2007-10-08 Processes for the preparation of crystalline atorvastatin hemicalcium form
NO20075721A NO20075721L (en) 2005-04-08 2007-11-08 New crystalline atorvastatin hemicalcium salt polymorph form
BG10109992A BG66035B1 (en) 2005-04-08 2007-11-08 New crystalline atorvastatin hemicalcium salt polymorph form
HK08105767.2A HK1117141A1 (en) 2005-04-08 2008-05-23 Process for the preparation of a new crystalline atorvastatin hemicalcium salt polymorph form

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
HU0600120A HUP0600120A3 (en) 2006-02-14 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it

Publications (3)

Publication Number Publication Date
HU0600120D0 HU0600120D0 (en) 2006-04-28
HUP0600120A2 true HUP0600120A2 (en) 2007-09-28
HUP0600120A3 HUP0600120A3 (en) 2010-01-28

Family

ID=89986584

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0600120A HUP0600120A3 (en) 2005-04-08 2006-02-14 New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it

Country Status (1)

Country Link
HU (1) HUP0600120A3 (en)

Also Published As

Publication number Publication date
HU0600120D0 (en) 2006-04-28
HUP0600120A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
CA2435954A1 (en) Preparation of non-crystalline atorvastatin calcium
WO2005105738A3 (en) Salt forms of atorvastatin
RS20110313A (en) Atorvastatin calcium in pharmaceutical form, composition thereof, and pharmaceutical formulation comprising atorvastation calcium
RS100003A (en) Crystalline forms of /r-(r*,r*)-2-(4- fluorphenyl)-beta,delta -dihydroxy-5(1- methylethyl)-phenyl-4-/phenylamino) carbonyl/-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
NZ312907A (en) Crystalline [r-(r*,r*)]-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl
IL177378A0 (en) Form iii crystalline (r-r*r*)-2-(4-fluorophenyl)-beta-delta-dihydroxy-5-(1-methylethyl)3-phenyl-4-(phenylamino)carbonyl)-ih-pyrrole-1-heptanoic acid hemi calcium salt ( atorvastatin)
PT1341785E (en) Hydrolysis of r(r*,r*)-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- [(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
TW200724688A (en) Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
WO2005014539A3 (en) Pyrrole-based hmg-coa reductase inhibitors
TW200738624A (en) Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
WO2006106372A8 (en) New crystalline atorvastatin hemicalcium salt polymorph form
HUP0600120A2 (en) New crystalline atorvastatin hemicalcium, pharmaceutical composition containing it and process for producing it
WO2008010087A3 (en) Polymorphic forms of an hmg-coa reductase inhibitor and uses thereof
CA2573771A1 (en) Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta., .gamma.-dihydroxy-5-(1-menthylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1)
WO2009007856A3 (en) Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
AR045654A1 (en) CRYSTAL ACID FORMS R- (R *, R *) - 2- (4- FLUOROPHENYL) -, DIHYDROXI - 5- (1- METHYLETHYL) - 3- PHENYL- 4- (PHENYLAMINE) - CARBONIL- 1H- PIRROL-1 - HEPTANOIC
UA93202C2 (en) Crystalline atorvastatin hemicalcium salt polymorph form
CA2521792A1 (en) Crystalline forms of [r-(r*,r*)]-2-(4-fluorophenyl)-beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt(2:1)(atorvastatin)

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished